Antioxidant, antinociceptive and anti-inflammatory activities of atorvastatin and rosuvastatin in various experimental models.
The present study was planned to investigate the antioxidant, antinociceptive, and anti-inflammatory activities of atorvastatin and rosuvastatin (1, 3 and 10 mg/kg, p.o.) in various animal models. The antinociceptive effect was assessed by chemically- (formalin, acetic acid) and thermally- (hot plate) induced nociception, while anti-inflammatory effect was evaluated using carrageenan-, formaldehyde-induced paw oedema and cotton pellet-induced granuloma. The effect of atorvastatin and rosuvastatin on liver antioxidant enzymes like superoxide dismutase, glutathione, LPO, CAT along with the effect on lactate dehydrogenase (LDH) and alkaline phosphatase (ALP) was evaluated in the cotton pellet-induced granuloma model. Atorvastatin and rosuvastatin showed significant decrease (p < 0.05) in carrageenan- and formaldehyde-induced rat paw oedema and reduced granuloma formation in the cotton pellet-induced granuloma method (p < 0.01) while the levels of LDH and ALP were also significantly decreased (p < 0.05). The liver antioxidant enzyme levels were found to be restored (p < 0.05). Atorvastatin and rosuvastatin also showed antinociceptive activities (p < 0.05 and p < 0.01) in the acetic acid- and formalin-induced nociception in mice, while there was no significant activity in the hot plate method. The present findings suggest that atorvastatin and rosuvastatin possess dose-dependent antioxidant, analgesic, and anti-inflammatory activities.
Ghaisas
Mahesh M
MM
Indira College of Pharmacy, Tathawade, Pune, India. ghaisasmm@yahoo.com
Dandawate
Prasad R
PR
Zawar
Suyash A
SA
Ahire
Yogesh S
YS
Gandhi
Santosh P
SP
D000469:Alkaline Phosphatase / Q000378:metabolism; D000700:Analgesics / Q000627:therapeutic use* / Q000633:toxicity; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use* / Q000633:toxicity; D000975:Antioxidants / Q000627:therapeutic use* / Q000633:toxicity; D000069059:Atorvastatin; D004487:Edema / Q000139:chemically induced / Q000188:drug therapy; D005464:Fluorobenzenes / Q000627:therapeutic use* / Q000633:toxicity; D006099:Granuloma / Q000188:drug therapy; D006538:Heptanoic Acids / Q000627:therapeutic use* / Q000633:toxicity; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D008099:Liver / Q000187:drug effects / Q000201:enzymology; D051379:Mice; D010146:Pain / Q000188:drug therapy; D010147:Pain Measurement; D011743:Pyrimidines / Q000627:therapeutic use* / Q000633:toxicity; D011758:Pyrroles / Q000627:therapeutic use* / Q000633:toxicity; D051381:Rats; D017208:Rats, Wistar; D000068718:Rosuvastatin Calcium; D013276:Stomach Ulcer / Q000139:chemically induced; D013449:Sulfonamides / Q000627:therapeutic use* / Q000633:toxicity
D000700:Analgesics; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000975:Antioxidants; D005464:Fluorobenzenes; D006538:Heptanoic Acids; D011743:Pyrimidines; D011758:Pyrroles; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium; D000069059:Atorvastatin; D007770:L-Lactate Dehydrogenase; D000469:Alkaline Phosphatase